Literature DB >> 19748318

A simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria.

Nageshwar R Budha1, Robin B Lee, Julian G Hurdle, Richard E Lee, Bernd Meibohm.   

Abstract

In vivo tuberculosis is exposed to continually changing drug concentrations for which static minimum inhibitory concentration (MIC) testing may be a poor surrogate. While in vitro approaches to determine time-kill curves for antibiotics have been widely applied in assessing antimicrobial activity against fast growing microorganisms, their availability and application for slow-growing microorganisms including Mycobacterium tuberculosis has so far been scarce. Thus, we developed a novel simple in vitro pharmacokinetic/pharmacodynamic (PK/PD) model for establishing time-kill curves and applied it for evaluating the antimicrobial activity of different dosing regimens of isoniazid (INH) against Mycobacterium bovis BCG as a surrogate for virulent M. tuberculosis. In the in vitro model M. bovis BCG was exposed to INH concentration-time profiles as usually encountered during multiple dose therapy with 25, 100 and 300mg/day in humans who are fast or slow INH metabolizers. Bacterial killing was followed over time by determining viable counts and the resulting time-kill data was analyzed using a semi-mechanistic PK/PD model with an adaptive IC(50) function to describe the emergence of insensitive populations of bacteria over the course of treatment. In agreement with previous studies, the time-kill data suggest that AUC(0-24)/MIC is the PK/PD index that is the most explanatory of the antimicrobial effect of INH. The presented in vitro PK/PD model and associated modeling approach were able to characterize the time-kill kinetics of INH in M. bovis BCG, and may in general serve as a potentially valuable, low cost tool for the assessment of antibacterial activity in slow-growing organisms in drug development and applied pharmacotherapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19748318      PMCID: PMC2783979          DOI: 10.1016/j.tube.2009.08.002

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  38 in total

1.  Biphasic kinetics of bacterial killing by quinolones.

Authors:  G Carret; J P Flandrois; J R Lobry
Journal:  J Antimicrob Chemother       Date:  1991-03       Impact factor: 5.790

2.  Application of logistic growth model to pharmacodynamic analysis of in vitro bactericidal kinetics.

Authors:  Y Yano; T Oguma; H Nagata; S Sasaki
Journal:  J Pharm Sci       Date:  1998-10       Impact factor: 3.534

3.  Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion.

Authors:  J W Mouton; A A Vinks; N C Punt
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

4.  Modelling time-kill studies to discern the pharmacodynamics of meropenem.

Authors:  Vincent H Tam; Amy N Schilling; Michael Nikolaou
Journal:  J Antimicrob Chemother       Date:  2005-03-16       Impact factor: 5.790

5.  Bactericidal activity of two different dosage regimens of imipenem in an in-vitro dynamic model.

Authors:  F Maggiolo; A Taras; S Frontespezi; F Bottari; M C Legnani; F Suter
Journal:  J Antimicrob Chemother       Date:  1993-08       Impact factor: 5.790

6.  New in vitro kinetic model for evaluating bactericidal efficacy of antibiotics.

Authors:  T Murakawa; H Sakamoto; T Hirose; M Nishida
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

7.  Pharmacokinetic-pharmacodynamic modelling of the in vitro antiinfective effect of piperacillin-tazobactam combinations.

Authors:  T Dalla Costa; A Nolting; K Rand; H Derendorf
Journal:  Int J Clin Pharmacol Ther       Date:  1997-10       Impact factor: 1.366

8.  Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis.

Authors:  Ramesh Jayaram; Radha K Shandil; Sheshagiri Gaonkar; Parvinder Kaur; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharath; E Kantharaj; V Balasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

9.  Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.

Authors:  Tawanda Gumbo; Arnold Louie; Mark R Deziel; Linda M Parsons; Max Salfinger; George L Drusano
Journal:  J Infect Dis       Date:  2004-09-24       Impact factor: 5.226

10.  Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin.

Authors:  Tawanda Gumbo; Arnold Louie; Mark R Deziel; Weiguo Liu; Linda M Parsons; Max Salfinger; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

View more
  15 in total

1.  In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis.

Authors:  Prakash M Jeena; William R Bishai; Jotam G Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-11-22       Impact factor: 5.191

2.  Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties.

Authors:  David Bruhn; Dora B Madhura; Marcus Maddox; Robin B Lee; Ashit Trivedi; Lei Yang; Michael S Scherman; Janet C Gilliland; Veronica Gruppo; Michael R McNeil; Anne J Lenaerts; Bernd Meibohm; Richard E Lee
Journal:  Bioorg Med Chem       Date:  2012-08-28       Impact factor: 3.641

Review 3.  Translational PK/PD of anti-infective therapeutics.

Authors:  Chetan Rathi; Richard E Lee; Bernd Meibohm
Journal:  Drug Discov Today Technol       Date:  2016-10-28

4.  A multi-scale approach to designing therapeutics for tuberculosis.

Authors:  Jennifer J Linderman; Nicholas A Cilfone; Elsje Pienaar; Chang Gong; Denise E Kirschner
Journal:  Integr Biol (Camb)       Date:  2015-04-30       Impact factor: 2.192

Review 5.  In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB.

Authors:  Pavan K Vaddady; Richard E Lee; Bernd Meibohm
Journal:  Future Med Chem       Date:  2010-08       Impact factor: 3.808

6.  A computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatment.

Authors:  Elsje Pienaar; Nicholas A Cilfone; Philana Ling Lin; Véronique Dartois; Joshua T Mattila; J Russell Butler; JoAnne L Flynn; Denise E Kirschner; Jennifer J Linderman
Journal:  J Theor Biol       Date:  2014-12-09       Impact factor: 2.691

7.  Anti-tuberculosis effect of isoniazid scales accurately from zebrafish to humans.

Authors:  Rob C van Wijk; Wanbin Hu; Sharka M Dijkema; Dirk-Jan van den Berg; Jeremy Liu; Rida Bahi; Fons J Verbeek; Ulrika S H Simonsson; Herman P Spaink; Piet H van der Graaf; Elke H J Krekels
Journal:  Br J Pharmacol       Date:  2020-11-03       Impact factor: 8.739

Review 8.  Applications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives.

Authors:  Ashit Trivedi; Richard E Lee; Bernd Meibohm
Journal:  Expert Rev Clin Pharmacol       Date:  2013-03       Impact factor: 5.045

Review 9.  PK/PD models in antibacterial development.

Authors:  Tony Velkov; Phillip J Bergen; Jaime Lora-Tamayo; Cornelia B Landersdorfer; Jian Li
Journal:  Curr Opin Microbiol       Date:  2013-07-18       Impact factor: 7.934

Review 10.  Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.

Authors:  Antonello Di Paolo; Giovanni Gori; Carlo Tascini; Romano Danesi; Mario Del Tacca
Journal:  Clin Pharmacokinet       Date:  2013-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.